Published in Pharmacol Biochem Behav on December 01, 1992
Assessment of reinforcing effects of benztropine analogs and their effects on cocaine self-administration in rats: comparisons with monoamine uptake inhibitors. J Pharmacol Exp Ther (2009) 1.66
Faster onset and dopamine transporter selectivity predict stimulant and reinforcing effects of cocaine analogs in squirrel monkeys. Pharmacol Biochem Behav (2006) 1.28
Dopamine transport inhibitors based on GBR12909 and benztropine as potential medications to treat cocaine addiction. Biochem Pharmacol (2007) 1.20
Relationship between rate of drug uptake in brain and behavioral pharmacology of monoamine transporter inhibitors in rhesus monkeys. Pharmacol Biochem Behav (2008) 1.17
Effect of the mGluR5 antagonist 6-methyl-2-(phenylethynyl)pyridine (MPEP) on the acute locomotor stimulant properties of cocaine, D-amphetamine, and the dopamine reuptake inhibitor GBR12909 in mice. Psychopharmacology (Berl) (2004) 0.92
Regional effects of amphetamine, cocaine, nomifensine and GBR 12909 on the dynamics of dopamine release and metabolism in the rat brain. Br J Pharmacol (1994) 0.81
Daily monitoring of dopamine efflux reveals a short-lasting occlusion of the dopamine agonist properties of d-amphetamine by dopamine transporter blockers GBR 12909 and methylphenidate. ACS Chem Neurosci (2013) 0.76
Reinforcing Doses of Intravenous Cocaine Produce Only Modest Dopamine Uptake Inhibition. ACS Chem Neurosci (2016) 0.76
Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci (1991) 5.88
Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A (1990) 5.48
Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse (2001) 4.03
Which clinical anesthesia outcomes are important to avoid? The perspective of patients. Anesth Analg (1999) 3.12
Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities. J Pharmacol Exp Ther (1993) 2.40
Sigma receptors: biology and function. Pharmacol Rev (1990) 2.37
Nicotinic binding in rat brain: autoradiographic comparison of [3H]acetylcholine, [3H]nicotine, and [125I]-alpha-bungarotoxin. J Neurosci (1985) 2.37
Comparison of bolus and infusion methods for receptor quantitation: application to [18F]cyclofoxy and positron emission tomography. J Cereb Blood Flow Metab (1993) 2.28
Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: relation to hypercortisolism and corticotropin-releasing hormone. Proc Natl Acad Sci U S A (2000) 2.19
Characterization and cloning of a novel glycoprotein expressed by stromal cells in T-dependent areas of peripheral lymphoid tissues. J Exp Med (1992) 2.11
(D-Ala2)-Met-enkephalinamide: a potent, long-lasting synthetic pentapeptide analgesic. Science (1976) 1.95
Cloning of murine Stat6 and human Stat6, Stat proteins that are tyrosine phosphorylated in responses to IL-4 and IL-3 but are not required for mitogenesis. Mol Cell Biol (1995) 1.85
Stereospecific and nonstereospecific effects of (+)- and (-)-morphine: evidence for a new class of receptors? Science (1977) 1.77
Characterization of two novel sigma receptor ligands: antidystonic effects in rats suggest sigma receptor antagonism. Eur J Pharmacol (1995) 1.73
Effects of corticotropin-releasing factor on neuronal activity in the serotonergic dorsal raphe nucleus. Neuropsychopharmacology (2000) 1.72
Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. Proc Natl Acad Sci U S A (2000) 1.69
Urban-rural differences in prehospital care of major trauma. J Trauma (1997) 1.58
In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: suppression of pituitary ACTH release and peripheral inflammation. Endocrinology (1996) 1.57
Opioid activation of toll-like receptor 4 contributes to drug reinforcement. J Neurosci (2012) 1.55
Substrate properties of site-specific mutant ubiquitin protein (G76A) reveal unexpected mechanistic features of ubiquitin-activating enzyme (E1). J Biol Chem (1994) 1.54
Identification of the first trans-(3R,4R)- dimethyl-4-(3-hydroxyphenyl)piperidine derivative to possess highly potent and selective opioid kappa receptor antagonist activity. J Med Chem (2001) 1.54
Pall leukotrap affinity prion-reduction filter removes exogenous infectious prions and endogenous infectivity from red cell concentrates. Vox Sang (2006) 1.50
Autoradiographic evidence for nicotine receptors on nigrostriatal and mesolimbic dopaminergic neurons. Brain Res (1985) 1.47
The hemodynamics of steal syndrome and its treatment. Ann Vasc Surg (1999) 1.46
Studies in the (+)-morphinan series. 5. Synthesis and biological properties of (+)-naloxone. J Med Chem (1978) 1.43
Effects of murine-derived anti-methamphetamine monoclonal antibodies on (+)-methamphetamine self-administration in the rat. J Pharmacol Exp Ther (2004) 1.42
Opioid peptide receptor studies. 14. Stereochemistry determines agonist efficacy and intrinsic efficacy in the [(35)S]GTP-gamma-S functional binding assay. Synapse (2001) 1.39
Mechanisms of reduced striatal NMDA excitotoxicity in type I nitric oxide synthase knock-out mice. J Neurosci (1997) 1.38
Perforated appendicitis within an inguinal hernia: case report and review of the literature. Am J Gastroenterol (1997) 1.37
Sites of morphine induced analgesia in the primate brain: relation to pain pathways. Brain Res (1974) 1.37
A pilot cohort study of granulocyte colony-stimulating factor in the treatment of unresponsive thin endometrium resistant to standard therapies. Hum Reprod (2012) 1.36
Fidelity and mutational spectrum of Pfu DNA polymerase on a human mitochondrial DNA sequence. Genome Res (1997) 1.34
Evidence that intrathecal morphine-3-glucuronide may cause pain enhancement via toll-like receptor 4/MD-2 and interleukin-1beta. Neuroscience (2010) 1.33
Oxidative stress-induced apoptosis of cochlear sensory cells: otoprotective strategies. Int J Dev Neurosci (2000) 1.31
Synthesis, opioid receptor binding, and biological activities of naltrexone-derived pyrido- and pyrimidomorphinans. J Med Chem (1999) 1.31
Electrophysiological actions of nicotine on substantia nigra single units. Br J Pharmacol (1985) 1.31
SNC 80, a selective, nonpeptidic and systemically active opioid delta agonist. J Pharmacol Exp Ther (1995) 1.30
Preferential increases in nucleus accumbens dopamine after systemic cocaine administration are caused by unique characteristics of dopamine neurotransmission. J Neurosci (2001) 1.30
Suppression of lymphokine-activated killer induction by neutrophils. J Immunol (1988) 1.27
Generation of anti-(+)methamphetamine antibodies is not impeded by (+)methamphetamine administration during active immunization of rats. Int Immunopharmacol (2001) 1.26
Identification of a homeodomain binding element in the bone sialoprotein gene promoter that is required for its osteoblast-selective expression. J Biol Chem (2000) 1.26
Nckbeta adapter regulates actin polymerization in NIH 3T3 fibroblasts in response to platelet-derived growth factor bb. Mol Cell Biol (2000) 1.24
Stereotype susceptibility in children: effects of identity activation on quantitative performance. Psychol Sci (2001) 1.23
Optical isomers of aryl-2-piperidylmethanol antimalarial agents. Preparation, optical purity, and absolute stereochemistry. J Med Chem (1974) 1.23
Possible involvement of toll-like receptor 4/myeloid differentiation factor-2 activity of opioid inactive isomers causes spinal proinflammation and related behavioral consequences. Neuroscience (2010) 1.22
Disseminated human immunodeficiency virus 1 (HIV-1) infection in SCID-hu mice after peripheral inoculation with HIV-1. J Exp Med (1994) 1.22
Presence and formation of codeine and morphine in the rat. Proc Natl Acad Sci U S A (1986) 1.20
Blockade of the serotonin 5-HT2A receptor suppresses cue-evoked reinstatement of cocaine-seeking behavior in a rat self-administration model. Behav Neurosci (2009) 1.20
About the origin of retroviruses and the co-evolution of the gypsy retrovirus with the Drosophila flamenco host gene. Genetica (1997) 1.19
Characterization of the flamenco region of the Drosophila melanogaster genome. Genetics (2001) 1.19
Structurally distinct nicotine immunogens elicit antibodies with non-overlapping specificities. Biochem Pharmacol (2011) 1.18
Divergent effects of chronic HIV-1 infection on human thymocyte maturation in SCID-hu mice. J Immunol (1995) 1.18
Convulsive effects of systemic administration of the delta opioid agonist BW373U86 in mice. J Pharmacol Exp Ther (1993) 1.17
Corticotropin-releasing hormone promotes blastocyst implantation and early maternal tolerance. Nat Immunol (2001) 1.16
Self-administration of cocaine and the cocaine analog RTI-113: relationship to dopamine transporter occupancy determined by PET neuroimaging in rhesus monkeys. Synapse (2002) 1.14
Identification of an opioid kappa receptor subtype-selective N-substituent for (+)-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine. J Med Chem (1998) 1.14
Interaction of endogenous opioid peptides and other drugs with four kappa opioid binding sites in guinea pig brain. Peptides (1990) 1.14
Ligand-induced changes in surface mu-opioid receptor number: relationship to G protein activation? J Pharmacol Exp Ther (2000) 1.13
Three-vessel view of the fetal upper mediastinum: an easy means of detecting abnormalities of the ventricular outflow tracts and great arteries during obstetric screening. Ultrasound Obstet Gynecol (1997) 1.12
Antinociceptive effects of delta-opioid agonists in Rhesus monkeys: effects on chemically induced thermal hypersensitivity. J Pharmacol Exp Ther (2001) 1.11
Purification of the putative hormone-sensitive cyclic AMP phosphodiesterase from rat adipose tissue using a derivative of cilostamide as a novel affinity ligand. J Biol Chem (1987) 1.10
Opiate receptor affinities and behavioral effects of enkephalin: structure-activity relationship of ten synthetic peptide analogues. Life Sci (1976) 1.10
Stereostructure-activity relationship of opioid agonist and antagonist bivalent ligands. Evidence for bridging between vicinal opioid receptors. J Med Chem (1985) 1.09
Hallucinogen-like actions of 5-methoxy-N,N-diisopropyltryptamine in mice and rats. Pharmacol Biochem Behav (2006) 1.08
Conformationally restricted analogs of BD1008 and an antisense oligodeoxynucleotide targeting sigma1 receptors produce anti-cocaine effects in mice. Eur J Pharmacol (2001) 1.08
Distribution of opiate receptor subtypes and enkephalin and dynorphin immunoreactivity in the hippocampus of squirrel, guinea pig, rat, and hamster. J Comp Neurol (1987) 1.07
Evidence that tricyclic small molecules may possess toll-like receptor and myeloid differentiation protein 2 activity. Neuroscience (2010) 1.07
GBR12909 antagonizes the ability of cocaine to elevate extracellular levels of dopamine. Pharmacol Biochem Behav (1991) 1.07
Studies of tolerance and dependence with the delta-opioid agonist SNC80 in rhesus monkeys responding under a schedule of food presentation. J Pharmacol Exp Ther (2001) 1.06
Subtype-selective corticotropin-releasing factor receptor agonists exert contrasting, but not opposite, effects on anxiety-related behavior in rats. J Pharmacol Exp Ther (2007) 1.05
Neuronal localization of cannabinoid receptors and second messengers in mutant mouse cerebellum. Brain Res (1991) 1.04
Opioid receptors on cells of the immune system: evidence for delta- and kappa-classes. J Endocrinol (1989) 1.04
Labeling by [3H]1,3-di(2-tolyl)guanidine of two high affinity binding sites in guinea pig brain: evidence for allosteric regulation by calcium channel antagonists and pseudoallosteric modulation by sigma ligands. Mol Pharmacol (1991) 1.04
Autoradiographic distribution of nicotine receptors in rat brain. Brain Res (1984) 1.03
Rate of binding of various inhibitors at the dopamine transporter in vivo. Psychopharmacology (Berl) (1995) 1.02
Purification of the opiate receptor of NG108-15 neuroblastoma-glioma hybrid cells. Proc Natl Acad Sci U S A (1985) 1.02
Synthesis and evaluation of optically pure [3H]-(+)-pentazocine, a highly potent and selective radioligand for sigma receptors. FEBS Lett (1989) 1.02
A practical synthesis of the serotonin 5-HT2A receptor antagonist MDL 100907, its enantiomer and their 3-phenolic derivatives as precursors for [11C]labeled PET ligands. Bioorg Med Chem (2000) 1.02
Effects of phentermine and fenfluramine on extracellular dopamine and serotonin in rat nucleus accumbens: therapeutic implications. Synapse (2000) 1.02
Consumption of oxygen: a mitochondrial-generated progression signal of advanced cancer. Cell Death Dis (2012) 1.02
Evidence for a role of heat shock protein-90 in toll like receptor 4 mediated pain enhancement in rats. Neuroscience (2009) 1.02
Unilateral ureteral obstruction in early development alters renal growth: dependence on the duration of obstruction. J Urol (1999) 1.01
The periaqueductal gray matter mediates opiate-induced immunosuppression. Science (1989) 1.01
Neurochemical neutralization of methamphetamine with high-affinity nonselective inhibitors of biogenic amine transporters: a pharmacological strategy for treating stimulant abuse. Synapse (2000) 1.01
Cocaine use increases [3H]WIN 35428 binding sites in human striatum. Brain Res (1993) 1.01
Investigation of the N-substituent conformation governing potency and mu receptor subtype-selectivity in (+)-(3R, 4R)-dimethyl-4-(3-hydroxyphenyl)piperidine opioid antagonists. J Med Chem (1998) 1.01
Comparative localization of neurotensin receptors on nigrostriatal and mesolimbic dopaminergic terminals. Brain Res (1985) 1.01
CRF-induced seizures and behavior: interaction with amygdala kindling. Brain Res (1986) 1.00
Health indicators among low income women who report a history of sex work: the population based Northern California Young Women's Survey. Sex Transm Infect (2005) 1.00
Interaction of 5-HT2A and 5-HT2C receptors in R(-)-2,5-dimethoxy-4-iodoamphetamine-elicited head twitch behavior in mice. J Pharmacol Exp Ther (2010) 1.00
Resolution of antimalarial agents via complex formation with alpha-(2,4,5,7-tetranitro-9-fluorenylideneaminooxy) propionic acid. J Med Chem (1978) 1.00
Antioxidant function of recombinant human natural killer enhancing factor. Biochem Biophys Res Commun (1995) 1.00